CV Technologies changes name
This article was originally published in The Tan Sheet
Executive Summary
The Cold-FX manufacturer changes its name to Afexa Life Sciences as part of a broader rebranding plan. CV Technologies "did not convey our rigorous life sciences orientation, or support our plans to leverage our market-leading product as we launch new ones," Executive Chairman Jack Moffatt says April 1 after shareholders approved the name change. The Canadian company said in November that it may submit a new drug application to FDA and look to grow its presence the U.S. market (1"The Tan Sheet" Nov. 24, 2008, p. 9)
|
The Cold-FX manufacturer changes its name to Afexa Life Sciences as part of a broader rebranding plan. CV Technologies "did not convey our rigorous life sciences orientation, or support our plans to leverage our market-leading product as we launch new ones," Executive Chairman Jack Moffatt says April 1 after shareholders approved the name change. The Canadian company said in November that it may submit a new drug application to FDA and look to grow its presence the U.S. market (1 (Also see "NDA For Cold-fX Could Follow Trial On Treating Cancer-Related Infections" - Pink Sheet, 24 Nov, 2008.), p. 9). |